New partnership to advance research, improve outcomes for MS patients
The Alberta Multiple Sclerosis Collaboration, a partnership between the provincial government, Campus Alberta Neuroscience and Sanofi Genzyme Canada, will advance research and innovation to improve care and outcomes for MS patients.
It also supports economic diversification and growth by further developing Alberta’s knowledge-based sectors and attracting investments from industry partners.
“With the unusually high rates of Multiple Sclerosis in Alberta, it is important to support research opportunities like this one. Thanks to this innovative partnership, people with MS in Alberta and around the world will benefit from improved care and better health solutions. It’s our hope this will serve as a catalyst to attract other industry partners to join Sanofi Genzyme and our government in this collaboration.”
“Sanofi Genzyme recognizes that collaboration is essential to accelerate and facilitate research and health innovation. We are a proud partner in this venture that will ultimately improve the health of people living with MS.”
Alberta Economic Development and Trade is contributing $500,000 to Campus Alberta Neuroscience, a province-wide network of 250 research professionals working in neuroscience and mental health. Sanofi Genzyme Canada, a global biotechnology company, is matching that with a $500,000 investment as the first industry partner in the MS Collaboration.
“Through partnerships like the Alberta MS Collaboration and growing collaborations in neuroscience between the Neuroscience and Mental Health Institute in Edmonton, the Canadian Centre for Behavioral Neuroscience in Lethbridge, and the Hotchkiss Brain Institute in Calgary, we can make real progress in tackling brain health issues like MS.”
“We are excited that we have this opportunity to elevate MS research and treatment activities to the next level in our continuing battle to end MS.”
The MS Collaboration will showcase Alberta as a leader in research excellence. The collaboration is intended to help attract other multinational industry enterprises to partner with Alberta’s innovation system, acclerate health innovations, and provide economic and social benefits to Alberta.
Alberta has one of the highest rates of MS in the world, with about 340 out of every 100,000 Albertans diagnosed with MS.